KNTE — Kinnate Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $125.62m
- -$28.41m
- 28
- 38
- 57
- 35
Annual cashflow statement for Kinnate Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -12 | -35.8 | -89.8 | -116 | -113 |
| Depreciation | |||||
| Non-Cash Items | 0.039 | 2.48 | 17 | 20.3 | 15.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.4 | 3.01 | 1.62 | 6.37 | -3.7 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -10.5 | -30.2 | -71.1 | -89 | -100 |
| Capital Expenditures | — | -0.297 | -0.769 | -2.72 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -31.4 | -180 | -4.11 | 110 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | — | -31.7 | -181 | -6.83 | 110 |
| Financing Cash Flow Items | 74.2 | -0.017 | 34.6 | -0.406 | -9.13 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 80 | 351 | 36.2 | 1.16 | -7.81 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 69.5 | 289 | -215 | -94.7 | 2.01 |